Biogen Inc.
$249.59+$2.46 (+1.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $29.0B
- P/E
- 22.4x
- EV / EBITDA
- 12.5x
- Revenue
- $9.9B
- Net margin
- 13.1%
- ROCE
- 9.5%
Price chart
Technical chartScreen technicals →+48.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +2.7%
- 3M
- +16.4%
- 6M
- +32.9%
- 1Y
- +48.4%
- 5Y
- -3.0%
52-week range
Day change +$2.46 (+1.0%) from $247 to $250 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BIIB, bought on each weekday since 2021.
News & filings
What Biogen filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernReturn on equity of 7.1% against a peer median of 20.5%.
Strengths (1)
- Operating margin of 25.0% against a peer median of 16.8%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Read moreShow less
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 146.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $29.0B
- P/E
- 22.4x
- P/B
- 1.6x
- EV / EBITDA
- 12.5x
- EV / Sales
- 3.3x
- P/S
- 2.9x
- 52-week high
- $254.87
- 52-week low
- $164.42
Profitability
- Operating margin
- 25.0%
- Net margin
- 13.1%
- EBITDA margin
- 26.3%
- ROE
- 7.1%
- ROCE
- 9.5%
- ROA
- 4.4%
- Asset turnover
- 0.34
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $9.9B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 2.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -0.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -20.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $2.0B
Solvency
- Current ratio
- 2.68
- Debt / Equity
- 0.36
- Debt / Assets
- 0.22
- CFO / Net profit
- 1.71
- Cash / Market cap
- 10.4%
Where the revenue went
Of every $100 of FY2025 revenue, $13 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $2.4B |
| Revenue | Gross profit | $7.5B |
| Gross profit | Research and development | $1.8B |
| Gross profit | Selling, general and administrative | $2.4B |
| Gross profit | Other operating expenses | $805.2M |
| Gross profit | Operating income | $2.5B |
| Operating income | Pretax income | $1.6B |
| Operating income | Interest and other expense | $912.5M |
| Pretax income | Tax and other | $263.6M |
| Pretax income | Net income | $1.3B |
Revenue and net profit
Revenue grew 2.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $10.2B | $3.0B |
| FY2023 | $9.8B | $1.2B |
| FY2024 | $9.7B | $1.6B |
| FY2025 | $9.9B | $1.3B |
Cash flows
FY2025: $2.2B from operations, $2.0B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.4B | $1.1B |
| FY2023 | $1.5B | $1.2B |
| FY2024 | $2.9B | $2.5B |
| FY2025 | $2.2B | $2.0B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $9.9B+2.2%1Y
- EBITDA
- $2.6B-8.0%1Y
- Net profit
- $1.3B-20.8%1Y
- Cash from operations
- $2.2B-23.3%1Y
- Free cash flow
- $2.0B-21.7%1Y
- Revenue CAGR, 3Y
- -0.9%
- Net profit CAGR, 3Y
- -24.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $9.9B | $2.6B | $1.3B | $2.0B | 7.1% | +2.2% | -20.8% |
Monthly returns
Month-by-month returns of BIIB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $29.4B |
| Current assets | $9.0B |
| Non-current assets | $20.5B |
| Liabilities | $11.2B |
| Current liabilities | $3.3B |
| Non-current liabilities | $7.8B |
| Equity | $18.3B |
| Paid-in capital | $863.1M |
| Retained earnings | $20.6B |
| Treasury stock | $3.0B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BIIB highlighted.
P/E against peers
BIIB trades at 22.4x earnings against a peer median of 17.0x (a 32% premium).
Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Biogen Inc.BIIBthis companyP/E ↑ premium | $29.0B | 22.4x | 1.6x | 7.1% | 12.5x |
| Zoetis Inc.ZTS | $33.3B | 12.5x | 10.0x | 80.2% | 9.9x |
| IQVIA Holdings Inc.IQV | $31.2B | 22.9x | 4.8x | 20.9% | 13.0x |
| Centene CorporationCNC | $31.0B | -4.6x | 1.6x | -33.4% | -6.5x |
| GE HealthCare Technologies Inc.GEHC | $29.0B | 13.9x | 2.8x | 20.1% | 9.2x |
| ResMed Inc.RMD | $28.2B | 20.1x | 4.7x | 23.5% | 14.5x |
| DexCom, Inc.DXCM | $28.0B | 33.5x | 10.2x | 30.5% | 21.0x |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| Peer median | — | 17.0x | 4.8x | 20.5% | 13.0x |
Year-to-date ROI
BIIB since 1 January, against earlier years.
Historical volatility
BIIB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 28.5% |
| FY2023 | 18.8% |
| FY2024 | 23.6% |
| FY2025 | 25.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $9.9B |
| Cost of revenueCost Of Revenue | $2.4B |
| Gross profitGross Profit | $7.5B |
| Operating expensesOperating Expense | $5.0B |
| Research and developmentResearch And Development | $1.8B |
| Selling, general and administrativeSelling General And Administration | $2.4B |
| Other operating expensesOther Operating Expenses | $290.2M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $515.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $515.0M |
| Amortization | $515.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $515.0M |
| Total expensesTotal Expenses | $7.4B |
| Operating incomeOperating Income | $2.5B |
| Interest and other | |
| Pretax incomePretax Income | $1.6B |
| TaxTax Provision | $263.6M |
| Net incomeNet Income | $1.3B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $29.4B |
| Current assetsCurrent Assets | $9.0B |
| Non-current assetsTotal Non Current Assets | $20.5B |
| LiabilitiesTotal Liabilities Net Minority Interest | $11.2B |
| Current liabilitiesCurrent Liabilities | $3.3B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $7.8B |
| EquityTotal Equity Gross Minority Interest | $18.3B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $2.2B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $2.2B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.3B |
| Depreciation and amortisationDepreciation And Amortization | $779.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $779.9M |
| Depreciation | $272.8M |
| Amortization cash flowAmortization Cash Flow | $507.1M |
| Amortization of intangiblesAmortization Of Intangibles | $507.1M |
| Stock-based compensationStock Based Compensation | $290.8M |
| Deferred taxDeferred Tax | $361.6M |
| Deferred income taxDeferred Income Tax | $361.6M |
| Operating gains and lossesOperating Gains Losses | $19.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $19.3M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | $60.8M |
| Provision and write off of assetsProvisionand Write Offof Assets | — |
| Change in working capitalChange In Working Capital | -$1.1B |
| Other non-cash itemsOther Non Cash Items | $456.9M |
| Investing cash flowInvesting Cash Flow | -$1.4B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$1.4B |
| Capital expenditureCapital Expenditure | -$235.4M |
| Purchase of PP&EPurchase Of PPE | -$153.8M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$153.8M |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$1.3B |
| Sale of investmentsSale Of Investment | $79.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$1.2B |
| Purchase of intangiblesPurchase Of Intangibles | -$81.6M |
| Sale of intangiblesSale Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$81.6M |
| Other investing changesNet Other Investing Changes | $42.9M |
| Financing cash flowFinancing Cash Flow | -$301.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$301.9M |
| Debt issuedIssuance Of Debt | $1.7B |
| Debt repaidRepayment Of Debt | -$1.8B |
| Net debt issuedNet Issuance Payments Of Debt | -$16.9M |
| Long-term debt issuedLong Term Debt Issuance | $1.7B |
| Long-term debt repaidLong Term Debt Payments | -$1.8B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$16.9M |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | -$10.0M |
| Other financing chargesNet Other Financing Charges | -$275.0M |
| Change in cashChanges In Cash | $531.6M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 10,190.0% |
| Cash at the start of the yearBeginning Cash Position | $2.4B |
| Cash at the end of the yearEnd Cash Position | $3.0B |
| Free cash flowFree Cash Flow | $2.0B |
| Supplemental |
Learn while you research
Academy chapters picked for Biogen Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read